Research & Literature

NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Shulman HM, Cardona DM, Greenson JK, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015; (21(4)):589-603.

Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.

Curtis LM, Datiles MB, Steinberg SM, et al.

Haematologica 2015; (100(9)):1228-36 doi:10.3324/haematol.2015.124131.

Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead.

Krupski C, Jagasia M

Current hematologic malignancy reports 2015; (10(3)):183-91 doi:10.1007/s11899-015-0265-2.

Case report: An unusual presentation of oral acute graft-versus-host-disease in a haploidentical hematopoietic stem cell transplant recipient.

Hong C, Tang KS, Villegas M, Tan PL

Oral surgery, oral medicine, oral pathology and oral radiology 2016; (121(3)):e51-3.

Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L

Seminars in hematology 2016; (53(2)):90-7.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Holtan SG, Khera N, Levine JE, et al.

Blood 2016; (128(19)):2350-2358 doi:10.1182/blood-2015-09-669846.

A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

Törlén J, Ringdén O, Garming-Legert K, et al.

Haematologica 2016; (101(11)):1417-1425 doi:10.3324/haematol.2016.149294.

Classification systems for chronic graft-versus-host disease.

Lee SJ

Blood 2017; (129(1)):30-37 doi:10.1182/blood-2016-07-686642.

Multiple and Recurrent Squamous Cell Carcinoma of the Oral Cavity After Graft-Versus-Host Disease.

Weng X, Xing Y, Cheng B

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2017; (75(9)):1899-1905 doi:10.1016/j.joms.2017.02.012.

Gut microbiota and acute graft-versus-host disease.

Yoshioka K, Kakihana K, Doki N, Ohashi K

Pharmacological research 2017; (122()):90-95 doi:10.1016/j.phrs.2017.05.028.

Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.

Bergeron A, Cheng GS

Clinics in chest medicine 2017; (38(4)):607-621 doi:10.1016/j.ccm.2017.07.003.

Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Zeiser R, Blazar BR

The New England journal of medicine 2017; (377(22)):2167-2179 doi:10.1056/NEJMra1609337.

A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment.

Smith Knutsson E, Björk Y, Broman AK, et al.

Acta obstetricia et gynecologica Scandinavica 2018; (97(9)):1122-1129 doi:10.1111/aogs.13366.

Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Kerep AZ, Broome J, Pirsl F, et al.

Bone marrow transplantation 2019; (54(1)):76-84 doi:10.1038/s41409-018-0224-3.

ENDOCRINE COMPLICATIONS IN PATIENTS WITH GVHD.

Akirov A, Sawka AM, Ben-Barouch S, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(5)):485-490 doi:10.4158/EP-2018-0529.

Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status.

Agh T, Csanadi M, Voko Z, et al.

Expert review of hematology 2019; (12(5)):295-309 doi:10.1080/17474086.2019.1602036.

A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease.

Csanadi M, Agh T, Tordai A, et al.

Expert review of hematology 2019; (12(5)):311-323 doi:10.1080/17474086.2019.1605288.

Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al.

Blood 2019; (134(3)):304-316 doi:10.1182/blood.2019000216.

Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease.

Cid J, Carbassé G, Suárez-Lledó M, et al.

Transfusion 2019; (59(8)):2636-2642 doi:10.1111/trf.15384.

The gut microbiota in transplant patients.

Chong PP, Koh AY

Blood reviews 2020; (39()):100614 doi:10.1016/j.blre.2019.100614.

MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application.

Srinagesh HK, Ferrara JLM

Best practice & research. Clinical haematology 2019; (32(4)):101111 doi:10.1016/j.beha.2019.101111.

Biomarkers in acute graft-versus-host disease: new insights.

Srinagesh HK, Levine JE, Ferrara JLM

Therapeutic advances in hematology 2019; (10()):2040620719891358 doi:10.1177/2040620719891358.

Evaluation of the lower histologic threshold for gastric graft versus host disease.

Mostafa M, Hartley CP, Hagen CE

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(5)):962-970 doi:10.1038/s41379-019-0421-7.

Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease.

Kilgour JM, Wali G, Gibbons E, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020; (26(5)):e113-e127 doi:10.1016/j.bbmt.2020.01.022.

Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.

Khandelwal P, Yeh RF, Yu L, et al.

Transplantation 2021; (105(4)):891-896 doi:10.1097/TP.0000000000003327.

Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review.

Csanádi M, Ágh T, Farkas-Ráduly S, et al.

Expert review of hematology 2020; (13(10)):1119-1130 doi:10.1080/17474086.2020.1818065.

A clinical and histological comparison between acute cutaneous graft-versus-host disease and other maculopapular eruptions following hematopoietic stem cell transplantation: a retrospective cohort.

Chanprapaph K, Leerunyakul K, Niparuck P, Rutnin S

International journal of dermatology 2021; (60(1)):60-69 doi:10.1111/ijd.15186.

Allogenic stem cell transplant-associated acute graft versus host disease: a computational drug discovery text mining approach using oral and gut microbiome signatures.

Beckman MF, Morton DS, Bahrani Mougeot F, Mougeot JC

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021; (29(4)):1765-1779 doi:10.1007/s00520-020-05821-2.

Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes.

Song ZY, Ren HY, Dong YJ, et al.

Cancer management and research 2020; (12()):12287-12300 doi:10.2147/CMAR.S283855.

Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.

Mirgh S, Gokarn A, Punatar S, et al.

Transplant infectious disease : an official journal of the Transplantation Society 2021; (23(4)):e13576 doi:10.1111/tid.13576.

STING and transplantation: can targeting this pathway improve outcomes?

Bader CS, Jin L, Levy RB

Blood 2021; (137(14)):1871-1878 doi:10.1182/blood.2020008911.

A Case Report of Central Nervous System Graft-Versus-Host Disease and Literature Review.

Li M, Zhang Y, Guan Y, et al.

Frontiers in neurology 2021; (12()):621392 doi:10.3389/fneur.2021.621392.

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.

Greinix HT, Eikema DJ, Koster L, et al.

Haematologica 2022; (107(5)):1054-1063 doi:10.3324/haematol.2020.265769.

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.

Zeiser R, Polverelli N, Ram R, et al.

The New England journal of medicine 2021; (385(3)):228-238 doi:10.1056/NEJMoa2033122.

Clinical study of graft-versus-host disease prophylaxis in unrelated hematopoietic stem cell transplantation for pediatric nonmalignant diseases with different doses anti-human T-lymphocyte immunoglobulin.

Atay D, Akcay A, Yenigurbuz FD, et al.

Pediatric transplantation 2021; (25(8)):e14098 doi:10.1111/petr.14098.

Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease.

Goklemez S, Saligan LN, Pirsl F, et al.

Bone marrow transplantation 2021; (56(12)):2934-2939 doi:10.1038/s41409-021-01419-2.

Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.

Kasikis S, Baez J, Gandhi I, et al.

Bone marrow transplantation 2021; (56(11)):2869-2870 doi:10.1038/s41409-021-01442-3.

Nonclassical manifestations of acute GVHD.

Zeiser R, Teshima T

Blood 2021; (138(22)):2165-2172 doi:10.1182/blood.2021012431.

Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis.

Yang X, Li D, Xie Y

Frontiers in oncology 2021; (11()):717678 doi:10.3389/fonc.2021.717678.

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.

DeFilipp Z, Alousi AM, Pidala JA, et al.

Blood advances 2021; (5(20)):4278-4284 doi:10.1182/bloodadvances.2021004941.

Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.

Bhatt VR, Wang T, Chen K, et al.

Transplantation and cellular therapy 2022; (28(1)):34-42 doi:10.1016/j.jtct.2021.10.002.

A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.

Li J, Zhang X, Chen Y, et al.

Oxidative medicine and cellular longevity 2022; (2022()):2124627 doi:10.1155/2022/2124627.

MAIT cells and their implication in human oral diseases.

Jiang Q, Wang F, Yang JY, Zhou G

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2022; (71(9)):1041-1054 doi:10.1007/s00011-022-01600-3.

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.

Fan S, Huo WX, Yang Y, et al.

Frontiers in immunology 2022; (13()):954268 doi:10.3389/fimmu.2022.954268.

Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.

Jeppesen H, Gjærde LK, Lindegaard J, et al.

Transplantation and cellular therapy 2022; (28(12)):833.e1-833.e7 doi:10.1016/j.jtct.2022.08.016.

The development of post-transplant cyclophosphamide: Half a century of translational team science.

O'Donnell PV, Jones RJ

Blood reviews 2023; (62()):101034 doi:10.1016/j.blre.2022.101034.

A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.

Salhotra A, Sandhu K, O'Hearn J, et al.

Expert review of clinical immunology 2023; (19(3)):241-251 doi:10.1080/1744666X.2023.2152330.

Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation.

Gruber I, Koelbl O, Herr W, et al.

Radiation oncology (London, England) 2022; (17(1)):195 doi:10.1186/s13014-022-02161-9.

Acute GVHD: New approaches to clinical trial monitoring.

Spyrou N, Levine JE, Ferrara JLM

Best practice & research. Clinical haematology 2022; (35(4)):101400 doi:10.1016/j.beha.2022.101400.

Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.

Baumrin E, Loren AW, Falk SJ, et al.

Journal of the American Academy of Dermatology 2024; (90(1)):19-36 doi:10.1016/j.jaad.2022.12.023.

Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.

Baumrin E, Loren AW, Falk SJ, et al.

Journal of the American Academy of Dermatology 2024; (90(1)):1-16 doi:10.1016/j.jaad.2022.12.024.

[Vedolizumab for treatment of steroid-refractory intestinal acute graft-versus-host disease: two cases report and literature review].

Gao SC, Feng YM, Gao L, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2022; (43(12)):1046-1049 doi:10.3760/cma.j.issn.0253-2727.2022.12.013.

Patterns and Grading of Gastrointestinal Graft-Versus-Host Disease: A Clinicopathologic Correlation Study.

Kuş Öztürk S, Kırmızı A, Aras N, et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2023; (34(5)):516-524 doi:10.5152/tjg.2023.22012.

Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.

Chen X, Wang Y, Huang X, et al.

International immunopharmacology 2023; (117()):109746 doi:10.1016/j.intimp.2023.109746.

Role of abatacept in the prevention of graft-versus-host disease: current perspectives.

Ngwube A, Rangarajan H, Shah N

Therapeutic advances in hematology 2023; (14()):20406207231152644 doi:10.1177/20406207231152644.

[Impact of the type of hematopoietic stem-cell transplant on quality of life and psychopathology].

Janicsák H, Masszi T, Reményi P, et al.

Ideggyogyaszati szemle 2023; (76(1-2)):25-35 doi:10.18071/isz.76.0025.

Topical treatment of oral chronic graft-versus-host- disease in hematopoietic stem cell transplant recipients: A systematic review.

Haas L, Cruz-Pamplona M

Journal of clinical and experimental dentistry 2023; (15(5)):e420-e427 doi:10.4317/jced.60138.

Posttransplant cyclophosphamide beyond haploidentical transplantation.

Arcuri LJ, Ribeiro AAF, Hamerschlak N, Kerbauy MN

Annals of hematology 2024; (103(5)):1483-1491 doi:10.1007/s00277-023-05300-8.

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.

Akahoshi Y, Spyrou N, Hogan WJ, et al.

Blood advances 2023; (7(16)):4479-4491 doi:10.1182/bloodadvances.2023009885.

Complex interactions of cellular players in chronic Graft-versus-Host Disease.

Gail LM, Schell KJ, Łacina P, et al.

Frontiers in immunology 2023; (14()):1199422 doi:10.3389/fimmu.2023.1199422.

The MAGIC algorithm probability (MAP)-guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial.

Zeng Q, Zhang H, Kuang P, et al.

American journal of hematology 2023; (98(10)):1550-1558 doi:10.1002/ajh.27020.

ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.

Hamad N, Bilmon I, Chee L, et al.

Internal medicine journal 2023; (53(12)):2319-2329 doi:10.1111/imj.16255.

Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.

Kovalenko I, Saleem T, Shah M, et al.

Advances in hematology 2023; (2023()):9949961 doi:10.1155/2023/9949961.

Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.

Bhattarai A, Shah S, Yadav R, et al.

Hematology (Amsterdam, Netherlands) 2024; (29(1)):2293497 doi:10.1080/16078454.2023.2293497.

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

Penack O, Marchetti M, Aljurf M, et al.

The Lancet. Haematology 2024; (11(2)):e147-e159 doi:10.1016/S2352-3026(23)00342-3.

Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.

Nelson AM, Yang D, Jagielo AD, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(1)):34-42 doi:10.6004/jnccn.2023.7080.

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.

Murray A, Linn SM, Yu B, et al.

Bone marrow transplantation 2024; (59(6)):759-764 doi:10.1038/s41409-024-02249-8.

[Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].

Huang SQ, Huang RH, Quan Y, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(1)):54-61 doi:10.3760/cma.j.cn121090-20231008-00162.

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.

Etra A, El Jurdi N, Katsivelos N, et al.

Blood advances 2024; (8(12)):3284-3292 doi:10.1182/bloodadvances.2023011049.

The Application of Umbilical Cord Blood-derived Platelet Gel for Skin Ulcers Associated With Chronic Graft-Versus-Host Disease in Pediatrics: A Randomized Trial.

Mohseni R, Mahdavi Sharif P, Khosravi A, et al.

Transplantation and cellular therapy 2024; (30(7)):694.e1-694.e10 doi:10.1016/j.jtct.2024.04.013.

The Role of Extracorporeal Photopheresis in the Management of Graft Versus Host Disease: Narrative Review.

Berhan A, Damtie S, Almaw A, et al.

ImmunoTargets and therapy 2024; (13()):235-246 doi:10.2147/ITT.S457366.

Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant.

Pearson BG, Cortez RS, Khimani KS, Gupta PK

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2025; (60(1)):e11-e15 doi:10.1016/j.jcjo.2024.04.005.

[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(6)):525-533 doi:10.3760/cma.j.cn121090-20240608-00214.

Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study.

Kerbauy MN, Rocha FA, Arcuri LJ, et al.

Haematologica 2025; (110(3)):640-650 doi:10.3324/haematol.2024.285921.

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(8)):713-726 doi:10.3760/cma.j.cn121090-20240611-00217.

Healthcare Resource Utilization and Associated Costs in Patients With Chronic Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation in England.

Avenoso D, Davidson JA, Larvin H, et al.

Transplantation and cellular therapy 2024; (30(12)):1207.e1-1207.e11 doi:10.1016/j.jtct.2024.10.002.

Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease.

Wenger V, Zeiser R

Best practice & research. Clinical haematology 2024; (37(3)):101567 doi:10.1016/j.beha.2024.101567.

Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.

Abedin S, Hamadani M

Current hematologic malignancy reports 2024; (19(6)):246-255 doi:10.1007/s11899-024-00741-y.

Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model.

Sato S, Ogawa Y, Asai K, et al.

Scientific reports 2025; (15(1)):532 doi:10.1038/s41598-024-84380-6.

[Congenital neutropenia and acute graft-versus-host disease in an infant. A case report].

Huchim-Peña CJ, Catana-Gallegos E, Martín-Burgos NG, Pacheco-Sierra JEA

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2024; (71(4)):268-271 doi:10.29262/ram.v71i4.1405.

"They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.

Centracchio JA, Yang DG, Jagielo AD, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(2)):102 doi:10.1007/s00520-025-09153-x.

Ruxolitinib for pediatric acute and chronic graft-versus-host disease: a single-center retrospective study of efficacy and safety.

Cheng CY, Lu MY, Chang HH, et al.

Annals of hematology 2025; (104(1)):753-760 doi:10.1007/s00277-025-06225-0.

Toward Improving Initial Therapy of Acute Graft Versus Host Disease.

Mehta AK, Koreth J

American journal of hematology 2025; (100 Suppl 3()):40-54 doi:10.1002/ajh.27593.

Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers.

Levine JE

American journal of hematology 2025; (100 Suppl 3()):5-13 doi:10.1002/ajh.27594.

Dessicating stress triggers and exacerbates experimental ocular Graft-versus-host-disease.

Gehlsen U, Maass M, Stary D, et al.

The ocular surface 2025; (37()):236-246 doi:10.1016/j.jtos.2025.04.008.

Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.

Dexter T, Anthias C, Nicholson E

Immunotherapy 2025; (17(6)):409-418 doi:10.1080/1750743X.2025.2501928.

Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease.

Sanli NM, Karakuş E

Hematology, transfusion and cell therapy 2025; (47(3)):103835 doi:10.1016/j.htct.2025.103835.

Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease.

Ngo D, Tinajero J, Otoukesh S, et al.

Expert opinion on investigational drugs 2025; (34(5)):391-400 doi:10.1080/13543784.2025.2510667.

Acute graft-vs-host disease, pathophysiology, prevention, and treatment: Something old and something new.

Cohan N, Ramzi M, Dermarderosian A, Akhtari M

Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2026; (74(1)):3-15 doi:10.1177/10815589251359314.

New molecules in the therapy of chronic graft-versus-host disease.

Steiner L, Klein SA, Kreil S

Current opinion in hematology 2025; (32(6)):314-320 doi:10.1097/MOH.0000000000000893.

Optimizing anti-thymocyte globulin dosing in allogeneic hematopoietic stem cell transplantation: individualized approaches and clinical implications.

Wang H, Yang H, Du J, et al.

Frontiers in immunology 2025; (16()):1634157 doi:10.3389/fimmu.2025.1634157.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies.

Fuji S, Ohmoto A

Current opinion in immunology 2025; (97()):102662 doi:10.1016/j.coi.2025.102662.

Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.

Shiratori S, Suto K, Hasegawa Y, et al.

Transplantation and cellular therapy 2026; (32(3)):339.e1-339.e9 doi:10.1016/j.jtct.2025.10.035.

Pre-Administration of Akkermansia Muciniphila Prevents the Development of Severe Acute Graft-Versus-Host Disease in Systemic Organs.

Han JE, Lee DS, Jeong SW, et al.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026; (13(9)):e15982 doi:10.1002/advs.202415982.

Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Xie C, Shi L, Wei Z, et al.

Frontiers in medicine 2025; (12()):1680188 doi:10.3389/fmed.2025.1680188.

Effectiveness of Oral Psoralen + UV-A (PUVA) Therapy in the Treatment of Chronic Cutaneous Graft Versus Host Disease (GVHD): A Retrospective, Observational Study Analysis from a Tertiary Care Centre.

Sadhwani M, Kulkarni V, Melinkeri S

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(1)):132-137 doi:10.1007/s12288-025-01983-3.

Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force.

Markova A, Lee SJ, Modi B, et al.

Transplantation and cellular therapy 2026; (32(6)):644.e1-644.e19 doi:10.1016/j.jtct.2026.01.009.

Acute Graft-Versus-Host Disease After Deceased-Donor Liver Transplantation: A Case Report.

Kim MJ, Ahn KS, Kim TS, et al.

The American journal of case reports 2026; (27()):e951031 doi:10.12659/AJCR.951031.